当前位置: 首页 >> 检索结果
201. Pressure-Controlled Intermittent Coronary Sinus Occlusion (PiCSO) in Acute Myocardial Infarction: The PiCSO-AMI-I Trial.
作者: Giovanni Luigi De Maria.;John P Greenwood.;Azfar G Zaman.;Didier Carrié.;Pierre Coste.;Marco Valgimigli.;Miles Behan.;Colin Berry.;Andrejs Erglis.;Vasileios F Panoulas.;Eric Van Belle.;Christian Juhl Terkelsen.;Lukas Hunziker Munsch.;Ajay K Jain.;Jens Flensted Lassen.;Nick Palmer.;Gregg W Stone.;Adrian P Banning.
来源: Circ Cardiovasc Interv. 2024年17卷4期e013675页
Primary percutaneous coronary intervention (pPCI) has improved clinical outcomes in patients with ST-segment-elevation myocardial infarction. However, as many as 50% of patients still have suboptimal myocardial reperfusion and experience extensive myocardial necrosis. The PiCSO-AMI-I trial (Pressure-Controlled Intermittent Coronary Sinus Occlusion-Acute Myocardial Infarction-I) evaluated whether PiCSO therapy can further reduce myocardial infarct size (IS) in patients undergoing pPCI.
202. Quality of Life in Patients With Chronic Limb-Threatening Ischemia Treated With Revascularization.
作者: Matthew T Menard.;Alik Farber.;Richard J Powell.;Kenneth Rosenfield.;Michael S Conte.;Taye H Hamza.;John A Kaufman.;Mark J Cziraky.;Mark A Creager.;Michael D Dake.;Michael R Jaff.;Diane Reid.;George Sopko.;Christopher J White.;Michael B Strong.;Max van Over.;Emiliano Chisci.;Philip P Goodney.;Bruce Gray.;Ahmed Kayssi.;Jeffrey J Siracuse.;Niteesh K Choudhry.; .
来源: Circulation. 2024年149卷16期1241-1253页
In the BEST-CLI trial (Best Endovascular Versus Best Surgical Therapy for Patients With Chronic Limb-Threatening Ischemia), a prespecified secondary objective was to assess the effects of revascularization strategy on health-related quality of life (HRQoL).
203. A Prospective Randomized Trial of Direct Oral Anticoagulant Therapy With a Fully Magnetically Levitated LVAD: The DOT-HM3 Study.
作者: Ivan Netuka.;Zuzana Tucanova.;Peter Ivak.;Stanislav Gregor.;Dushan Michael Kolesar.;Tomas Marek.;Vojtech Melenovsky.;Jana Binova.;Zora Dorazilova.;Marketa Hegarova.;Martina Podolec.;Hynek Riha.;Jean M Connors.;Mandeep R Mehra.
来源: Circulation. 2024年150卷6期509-511页 204. Effect of Alcohol-Mediated Renal Denervation on Blood Pressure in the Presence of Antihypertensive Medications: Primary Results From the TARGET BP I Randomized Clinical Trial.
作者: David E Kandzari.;Michael A Weber.;Atul Pathak.;James P Zidar.;Manish Saxena.;Shukri W David.;Roland E Schmieder.;Adam J Janas.;Christopher Langer.;Alexandre Persu.;Farrell O Mendelsohn.;Koen Ameloot.;Malcolm Foster.;Tim A Fischell.;Helen Parise.;Felix Mahfoud.
来源: Circulation. 2024年149卷24期1875-1884页
Renal denervation (RDN) has demonstrated clinically relevant reductions in blood pressure (BP) among individuals with uncontrolled hypertension despite lifestyle intervention and medications. The safety and effectiveness of alcohol-mediated RDN have not been formally studied in this indication.
205. Topical Versus Intravenous Tranexamic Acid in Patients Undergoing Cardiac Surgery: The DEPOSITION Randomized Controlled Trial.
作者: André Lamy.;Dmitry A Sirota.;Frederic Jacques.;Ahmad Poostizadeh.;Nicolas Noiseux.;Sergey Efremov.;Philippe Demers.;Boris Akselrod.;Chew Yin Wang.;Rakesh C Arora.;Piotr Branny.;Shay P McGuinness.;Craig D Brown.;Hugues Jeanmart.;Qiang Zhao.;Haibo Zhang.;Emilie P Belley-Côté.;Richard P Whitlock.;Austin Browne.;Ingrid Copland.;Jessica Vincent.;Rutaba Khatun.;Kumar Balasubramanian.;Shrikant I Bangdiwala.;Michael H McGillion.;Alison E Fox-Robichaud.;Jessica Spence.;Salim Yusuf.;P J Devereaux.; .
来源: Circulation. 2024年150卷17期1315-1323页
Although intravenous tranexamic acid is used in cardiac surgery to reduce bleeding and transfusion, topical tranexamic acid results in lower plasma concentrations compared with intravenous tranexamic acid, which may lower the risk of seizures. We aimed to determine whether topical tranexamic acid reduces the risk of in-hospital seizure without increasing the risk of transfusion among cardiac surgery patients.
206. Clinical Impact of Routine Assessment of Patient-Reported Health Status in Heart Failure Clinic: The PRO-HF Trial.
作者: Alexander T Sandhu.;Jamie Calma.;Megan Skye.;Neil Kalwani.;Jimmy Zheng.;Jessica Schirmer.;Natasha Din.;Cati Brown Johnson.;Anshal Gupta.;Roy Lan.;Brian Yu.;John A Spertus.;Paul A Heidenreich.
来源: Circulation. 2024年149卷22期1717-1728页
The impact of routine clinic use of patient-reported outcome (PRO) measures on clinical outcomes in patients with heart failure (HF) has not been well-characterized. We tested if clinic-based use of a disease-specific PRO improves patient-reported quality of life at 1 year.
207. Randomized Evaluation of a Remote Management Program to Improve Guideline-Directed Medical Therapy: The DRIVE Trial.
作者: Alexander J Blood.;Lee-Shing Chang.;Shahzad Hassan.;Jacqueline Chasse.;Gretchen Stern.;Daniel Gabovitch.;David Zelle.;Caitlin Colling.;Samuel J Aronson.;Christian Figueroa.;Emma Collins.;Ryan Ruggiero.;Emily Zacherle.;Joshua Noone.;Carey Robar.;Jorge Plutzky.;Thomas A Gaziano.;Christopher P Cannon.;Deborah J Wexler.;Benjamin M Scirica.
来源: Circulation. 2024年149卷23期1802-1811页
Several SGLT2i (sodium-glucose transport protein 2 inhibitors) and GLP1-RA (glucagon-like peptide-1 receptor agonists) reduce cardiovascular events and improve kidney outcomes in patients with type 2 diabetes; however, utilization remains low despite guideline recommendations.
208. Effect of Gamification, Financial Incentives, or Both to Increase Physical Activity Among Patients at High Risk of Cardiovascular Events: The BE ACTIVE Randomized Controlled Trial.
作者: Alexander C Fanaroff.;Mitesh S Patel.;Neel Chokshi.;Samantha Coratti.;David Farraday.;Laurie Norton.;Charles Rareshide.;Jingsan Zhu.;Tamar Klaiman.;Julia E Szymczak.;Louise B Russell.;Dylan S Small.;Kevin G M Volpp.
来源: Circulation. 2024年149卷21期1639-1649页
Physical activity is associated with a lower risk of major adverse cardiovascular events, but few individuals achieve guideline-recommended levels of physical activity. Strategies informed by behavioral economics increase physical activity, but their longer-term effectiveness is uncertain. We sought to determine the effect of behaviorally designed gamification, loss-framed financial incentives, or their combination on physical activity compared with attention control over 12-month intervention and 6-month postintervention follow-up periods.
209. Effect of Empagliflozin on Heart Failure Outcomes After Acute Myocardial Infarction: Insights From the EMPACT-MI Trial.
作者: Adrian F Hernandez.;Jacob A Udell.;W Schuyler Jones.;Stefan D Anker.;Mark C Petrie.;Josephine Harrington.;Michaela Mattheus.;Svenja Seide.;Isabella Zwiener.;Offer Amir.;M Cecilia Bahit.;Johann Bauersachs.;Antoni Bayes-Genis.;Yundai Chen.;Vijay K Chopra.;Gemma A Figtree.;Junbo Ge.;Shaun G Goodman.;Nina Gotcheva.;Shinya Goto.;Tomasz Gasior.;Waheed Jamal.;James L Januzzi.;Myung Ho Jeong.;Yuri Lopatin.;Renato D Lopes.;Béla Merkely.;Puja B Parikh.;Alexander Parkhomenko.;Piotr Ponikowski.;Xavier Rossello.;Morten Schou.;Dragan Simic.;Philippe Gabriel Steg.;Joanna Szachniewicz.;Peter van der Meer.;Dragos Vinereanu.;Shelley Zieroth.;Martina Brueckmann.;Mikhail Sumin.;Deepak L Bhatt.;Javed Butler.
来源: Circulation. 2024年149卷21期1627-1638页
Empagliflozin reduces the risk of heart failure (HF) events in patients with type 2 diabetes at high cardiovascular risk, chronic kidney disease, or prevalent HF irrespective of ejection fraction. Whereas the EMPACT-MI trial (Effect of Empagliflozin on Hospitalization for Heart Failure and Mortality in Patients With Acute Myocardial Infarction) showed that empagliflozin does not reduce the risk of the composite of hospitalization for HF and all-cause death, the effect of empagliflozin on first and recurrent HF events after myocardial infarction is unknown.
210. SPECTRA Phase 2b Study: Impact of Sotatercept on Exercise Tolerance and Right Ventricular Function in Pulmonary Arterial Hypertension.
作者: Aaron B Waxman.;David M Systrom.;Solaiappan Manimaran.;Janethe de Oliveira Pena.;Jonathan Lu.;Franz P Rischard.
来源: Circ Heart Fail. 2024年17卷5期e011227页
This study aims to assess the impact of sotatercept on exercise tolerance, exercise capacity, and right ventricular function in pulmonary arterial hypertension.
211. Cardiovascular Effects of Oral Ketone Ester Treatment in Patients With Heart Failure With Reduced Ejection Fraction: A Randomized, Controlled, Double-Blind Trial.
作者: Kristoffer Berg-Hansen.;Nigopan Gopalasingam.;Kristian Hylleberg Christensen.;Bertil Ladefoged.;Mads Jønsson Andersen.;Steen Hvitfeldt Poulsen.;Barry A Borlaug.;Roni Nielsen.;Niels Møller.;Henrik Wiggers.
来源: Circulation. 2024年149卷19期1474-1489页
Heart failure triggers a shift in myocardial metabolic substrate utilization, favoring the ketone body 3-hydroxybutyrate as energy source. We hypothesized that 14-day treatment with ketone ester (KE) would improve resting and exercise hemodynamics and exercise capacity in patients with heart failure with reduced ejection fraction.
212. Impact of Incomplete Revascularization After PCI in Left Main Disease: The EXCEL Trial.
作者: Ziad A Ali.;Javier Jas Garcia.;Keyvan Karimi Galougahi.;Jennifer Horst.;Anthony Gallo.;Doosup Shin.;Ori Ben-Yehuda.;Shmuel Chen.;Björn Redfors.;Arie Pieter Kappetein.;Joseph F Sabik.;Patrick W Serruys.;Gregg W Stone.
来源: Circ Cardiovasc Interv. 2024年17卷3期e013192页
The importance of complete revascularization after percutaneous coronary intervention (PCI) in patients with left main coronary artery disease is uncertain. We investigated the clinical impact of complete revascularization in patients with left main coronary artery disease undergoing PCI in the EXCEL trial (Evaluation of XIENCE Versus Coronary Artery Bypass Surgery for Effectiveness of Left Main Revascularization).
213. Variation of NT-proBNP and High-Sensitivity Cardiac Troponin T Across Levels of Estimated Glomerular Filtration Rate: The SPRINT Trial.
作者: Nisha Bansal.;Ronit Katz.;Stephen Seliger.;Christopher deFilippi.;Nicholas Wettersten.;James A de Lemos.;Robert Christenson.;Anthony A Killeen.;Jarett D Berry.;Michael G Shlipak.;Joachim H Ix.
来源: Circulation. 2024年149卷12期967-969页 214. Cost-Effectiveness of Intravascular Imaging-Guided Complex PCI: Prespecified Analysis of RENOVATE-COMPLEX-PCI Trial.
作者: David Hong.;Jin Lee.;Hankil Lee.;Juhee Cho.;Eliseo Guallar.;Ki Hong Choi.;Seung Hun Lee.;Doosup Shin.;Jong-Young Lee.;Seung-Jae Lee.;Sang Yeub Lee.;Sang Min Kim.;Kyeong Ho Yun.;Jae Young Cho.;Chan Joon Kim.;Hyo-Suk Ahn.;Chang-Wook Nam.;Hyuck-Jun Yoon.;Yong Hwan Park.;Wang Soo Lee.;Taek Kyu Park.;Jeong Hoon Yang.;Seung-Hyuk Choi.;Hyeon-Cheol Gwon.;Young Bin Song.;Joo-Yong Hahn.;Danbee Kang.;Joo Myung Lee.; .
来源: Circ Cardiovasc Qual Outcomes. 2024年17卷3期e010230页
Although clinical benefits of intravascular imaging-guided percutaneous coronary intervention (PCI) in patients with complex coronary artery lesions have been observed in previous trials, the cost-effectiveness of this strategy is uncertain.
215. Impact of Rapid Up-Titration of Guideline-Directed Medical Therapies on Quality of Life: Insights From the STRONG-HF Trial.
作者: Jelena Čelutkienė.;Kamilė Čerlinskaitė-Bajorė.;Gad Cotter.;Christopher Edwards.;Marianna Adamo.;Mattia Arrigo.;Marianela Barros.;Jan Biegus.;Ovidiu Chioncel.;Alain Cohen-Solal.;Albertino Damasceno.;Rafael Diaz.;Gerasimos Filippatos.;Etienne Gayat.;Antoine Kimmoun.;Valentine Léopold.;Marco Metra.;Maria Novosadova.;Matteo Pagnesi.;Peter S Pang.;Piotr Ponikowski.;Hadiza Saidu.;Karen Sliwa.;Koji Takagi.;Jozine M Ter Maaten.;Daniela Tomasoni.;Carolyn S P Lam.;Adriaan A Voors.;Alexandre Mebazaa.;Beth Davison.
来源: Circ Heart Fail. 2024年17卷4期e011221页
This analysis provides details on baseline and changes in quality of life (QoL) and its components as measured by EQ-5D-5L questionnaire, as well as association with objective outcomes, applying high-intensity heart failure (HF) care in patients with acute HF.
216. Compression-Only or Standard Cardiopulmonary Resuscitation for Trained Laypersons in Out-of-Hospital Cardiac Arrest: A Nationwide Randomized Trial in Sweden.
作者: Gabriel Riva.;Erik Boberg.;Mattias Ringh.;Martin Jonsson.;Andreas Claesson.;Anette Nord.;Sten Rubertsson.;Hans Blomberg.;Per Nordberg.;Sune Forsberg.;Mårten Rosenqvist.;Leif Svensson.;Cecilia Andréll.;Johan Herlitz.;Jacob Hollenberg.
来源: Circ Cardiovasc Qual Outcomes. 2024年17卷3期e010027页
The ongoing TANGO2 (Telephone Assisted CPR. AN evaluation of efficacy amonGst cOmpression only and standard CPR) trial is designed to evaluate whether compression-only cardiopulmonary resuscitation (CPR) by trained laypersons is noninferior to standard CPR in adult out-of-hospital cardiac arrest. This pilot study assesses feasibility, safety, and intermediate clinical outcomes as part of the larger TANGO2 survival trial.
217. Left Atrial Strain Predicts Subclinical Atrial Fibrillation Detected by Long-term Continuous Monitoring in Elderly High-Risk Individuals.
作者: Flemming Javier Olsen.;Søren Zöga Diederichsen.;Peter Godsk Jørgensen.;Magnus T Jensen.;Anders Dahl.;Nino Emanuel Landler.;Claus Graff.;Axel Brandes.;Derk Krieger.;Ketil Haugan.;Lars Køber.;Søren Højberg.;Jesper Hastrup Svendsen.;Tor Biering-Sørensen.
来源: Circ Cardiovasc Imaging. 2024年17卷3期e016197页
Left atrial (LA) speckle tracking provides detailed information on atrial function. Its utility for predicting subclinical atrial fibrillation (SCAF) is unclear. Therefore, we sought to investigate whether LA strain measures could predict SCAF detected by long-term continuous rhythm monitoring.
218. Torsemide Versus Furosemide After Discharge in Patients Hospitalized With Heart Failure Across the Spectrum of Ejection Fraction: Findings From TRANSFORM-HF.
作者: Chris J Kapelios.;Stephen J Greene.;Robert J Mentz.;Uchechukwu Ikeaba.;Daniel Wojdyla.;Kevin J Anstrom.;Eric L Eisenstein.;Bertram Pitt.;Eric J Velazquez.;James C Fang.; .
来源: Circ Heart Fail. 2024年17卷3期e011246页
The TRANSFORM-HF trial (Torsemide Comparison With Furosemide for Management of Heart Failure) found no significant difference in all-cause mortality or hospitalization among patients randomized to a strategy of torsemide versus furosemide following a heart failure (HF) hospitalization. However, outcomes and responses to some therapies differ by left ventricular ejection fraction (LVEF). Thus, we sought to explore the effect of torsemide versus furosemide by baseline LVEF and to assess outcomes across LVEF groups.
219. Postprocedural Anticoagulation After Primary Percutaneous Coronary Intervention for ST-Segment-Elevation Myocardial Infarction: A Multicenter, Randomized, Double-Blind Trial.
作者: Yan Yan.;Jincheng Guo.;Xiao Wang.;Guozhong Wang.;Zeyuan Fan.;Delu Yin.;Zhifang Wang.;Fuchun Zhang.;Changming Tian.;Wei Gong.;Jiamin Liu.;Jiapeng Lu.;Yongjun Li.;Changsheng Ma.;Eric Vicaut.;Gilles Montalescot.;Shaoping Nie.; .
来源: Circulation. 2024年149卷16期1258-1267页
Postprocedural anticoagulation (PPA) is frequently administered after primary percutaneous coronary intervention in ST-segment-elevation myocardial infarction, although no conclusive data support this practice.
220. Cardiovascular Outcomes in GRADE (Glycemia Reduction Approaches in Type 2 Diabetes: A Comparative Effectiveness Study).
作者: Jennifer B Green.;Brendan M Everett.;Alokananda Ghosh.;Naji Younes.;Heidi Krause-Steinrauf.;Joshua Barzilay.;Cyrus Desouza.;Silvio E Inzucchi.;Yashashwi Pokharel.;David Schade.;Alexandra Scrymgeour.;Meng H Tan.;Kristina M Utzschneider.;Sunder Mudaliar.; .
来源: Circulation. 2024年149卷13期993-1003页
Cardiovascular disease is a major cause of morbidity and mortality in patients with type 2 diabetes. The effects of glucose-lowering medications on cardiovascular outcomes in individuals with type 2 diabetes and low cardiovascular risk are unclear. We investigated cardiovascular outcomes by treatment group in participants randomly assigned to insulin glargine, glimepiride, liraglutide, or sitagliptin, added to baseline metformin, in GRADE (Glycemia Reduction Approaches in Type 2 Diabetes: A Comparative Effectiveness Study).
|